Green tea extract supplements, reviewed with the safety literature attached
A staple of fat-burner formulas, and the one ingredient here where the most important published finding is about harm rather than benefit.
Green tea extract sits in a large share of the fat-burner formulas on the market, usually near the top of the panel and usually described in terms of metabolism. It is one of the more studied ingredients in this category. It is also the one where, in our reading, the most consequential published work concerns safety rather than efficacy — and that ordering is not reflected in how it is sold.
Updated 7 November 2026: details are re-sourced to primary documents, and lines with no primary document are cut.
Updated 6 November 2026: the score is removed; this is now an assessment of published documents, listed below. Corrected: EFSA’s Panel noted uncertainty in identifying a maximum dose that does not raise liver enzymes.
So we are going to review it the other way round from the marketing: risk first.
The safety finding
Three things about that table deserve emphasis, and all three are routinely lost.
The finding is about supplements, not tea. EFSA drew a clear distinction: the concern attaches to concentrated extract in supplement form, not to drinking green tea. Anyone reading this as a reason to stop drinking tea has read it backwards.
The number is EGCG, not extract. A label stating “green tea extract 500 mg” is not stating an EGCG dose. Extracts are standardised to varying catechin percentages, and the EGCG content is the figure the assessment concerns. Where a label does not state EGCG content, the buyer cannot perform the relevant comparison at all — and a good many labels do not state it.
Stacking is where the number is quietly reached. A single product may sit comfortably below the threshold. Two products taken together, both containing green tea extract, may not. Multi-product regimens are common in this category and no individual label accounts for them.
The UK Committee on Toxicity’s 2024 statement on the hepatotoxicity of green tea catechins, as summarised in its July 2026 meeting paper, concluded that studies did not identify effects of EGCG in humans below 800 mg/day, but that a few individuals could still react below that dose idiosyncratically. Anyone with existing liver concerns, or taking medication, should treat this as a conversation for a clinician rather than something to resolve from a product page.
The efficacy side, briefly
Having led with the risk, we should be fair about the benefit — and being fair means being modest.
Research on green tea catechins and body weight has generally reported effects that are small, variable between studies, and often measured over short periods in specific populations. Some work has explored interactions with caffeine, which most of these formulas also contain, making attribution to any single component difficult.
The honest summary is that this is a well-studied ingredient with modest and inconsistent findings on the outcome buyers care about. That is not nothing. It is a long way from what “thermogenic” implies on the front of a box.
These products are not evaluated by the FDA and are not intended to diagnose, treat, cure or prevent any disease, and no supplement is a substitute for medical care. Nothing here is medical advice.
What a defensible label looks like
It states EGCG content in milligrams, not just extract weight. It states servings per day so the daily total can be calculated. It carries whatever warning its market requires and does not bury it. And it does not describe the ingredient in language its own evidence does not support.
Labels that do all four exist. They are not the majority.
Pros and cons
Our assessment
This is an assessment of published documents, not of using any product: a well-researched ingredient whose clearest published finding is about liver risk at high supplemental doses. Modest benefit, real and specific caution, and labels that frequently withhold the one number that matters.
Our position is that green tea extract is not a scandal and not a solution. If a product states its EGCG content, keeps the daily total well clear of the 800 mg level EFSA named, and does not oversell what the ingredient does, it is a defensible thing to sell, though EFSA’s Panel noted uncertainty about a maximum dose that does not raise liver enzymes, and the UK COT could not exclude idiosyncratic reactions below 800 mg/day, so that level is no guarantee. If a label states only extract weight — and particularly if you are taking more than one product containing it — you are dosing an ingredient by a number the label declined to give you. That is the part we would not accept.
Documents read
Read on 6 November 2026:
-
EFSA news item on green tea catechins (18 Apr 2018): doses of EGCG at or above 800 mg/day from food supplements may pose health concerns / may be associated with initial signs of liver damage.
-
EFSA Journal scientific opinion on the safety of green tea catechins (2018), via serper-scrape: opinion on green tea catechins in foods incl. supplements and infusions.
-
UK COT July 2026 paper: Herb Induced Liver Injury: Cites COT’s 2024 statement on green tea catechins: no human effects of EGCG identified below 800 mg/day, idiosyncratic reactions below that dose not excluded.